Objectives:
Phase I part
- Primary Objective: To determine the recommended dose of the combination of lapatinib
with Lipo-Dox as first line chemotherapy in patients with ErbB2 positive metastatic
breast cancer.
- Secondary Objectives:To define the safety profile; To observe the response rate and
progression free survival
Phase II part
- Primary Objective :To determined the objective response rate of the combination of
lapatinib with Lipo-Dox as first line chemotherapy in patients with ErbB2 positive
metastatic breast cancer.
- Secondary Objectives:To define the safety profile; To determined the progression free
survival